Latest total liabilities for LYRA: $47M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Lyra Therapeutics (LYRA) currently reports a total liabilities of $47M as of December 2025. That compares with $55M in the prior-year period — down 14.5% year over year. Use the charts on this page to explore Lyra Therapeutics's total liabilities history and peer comparisons.
Lyra Therapeutics's total liabilities decreased from $55M to $47M — a 14.5% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Lyra Therapeutics reported $47M in total liabilities as of December 2025. That compares with $55M in the prior-year period — down 14.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total liabilities of $47M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lyra Therapeutics, and consider following LYRA for alerts when major investors trade the stock.
Lyra Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $47M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LYRA with unrelated industries.